ClinicalTrials.gg
RecruitingNCT06943755STELLAR-311Updated Oct 30, 2026

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

A Phase 2/3 interventional study of Zanzalintinib and Everolimus in Pancreatic Neuroendocrine Tumor (pNET) and Extra-Pancreatic Neuroendocrine Tumor (epNET), sponsored by Exelixis. Recruiting at 135 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Exelixis · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 30, 2026First site in Mexico9 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Adenoma, Islet Cell with a site in United States — 13 open to participants now, 21 under way, 4 of them phase 3. Adenoma, Islet Cell · United States.

Planned enrollment
2nd of 51
440 · median 39
Started
2025
with 3 others
Phase 2/3
2 of 59
1 open now
Primary completion
2029-06
later than 19 of 20 live
Registered
55th of 59
by date

Among the 59 studies in Adenoma, Islet Cell with a site in United States, this one is the 2nd largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2025, is one of 2 in phase 2/3, reaches primary completion later than 19 of the 20 other live ones, and was the 55th registered.

Adenoma, Islet Cell

113 studies on the registry are indexed under Adenoma, Islet Cell; 30 are open to participants now.

Browse Adenoma, Islet Cell studies →

Open to participants now

13 of the 59 studies in Adenoma, Islet Cell with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Adenoma, Islet Cell studies recruiting now, 17 (71%) set no upper age limit and 2 (8%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Adenoma, Islet Cell with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

03

Conditions studied

  • Pancreatic Neuroendocrine Tumor (pNET)
  • Extra-Pancreatic Neuroendocrine Tumor (epNET)

Keywords

  • Metastatic Cancer
  • Locally Advanced Cancer
  • Neuroendocrine Tumor (NET)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed, locally advanced/unresectable or , well-differentiated Grade 1, 2, or 3 NETs of pancreatic origin or extra-pancreatic origin.
  • Allowed , based on the site of NET and functional status.
  • Documented radiographic disease progression per 1.1, as assessed by the Investigator based on imaging assessments (computed tomography [CT] or magnetic resonance imaging [MRI]) within 12 months before randomization.
  • according to RECIST 1.1 as determined by the Investigator.
  • is required, if available. If archival tumor tissue is not available, a fresh biopsy may be submitted if it can be safely and feasibly obtained. Every attempt should be made to provide tumor tissue.

Key Exclusion Criteria:

  • Histologically confirmed neuroendocrine carcinomas (including small cell lung cancer), medullary thyroid cancer, pheochromocytoma, paraganglioma, Merkel cell carcinoma, and mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN).
  • Prior treatment with a vascular endothelial growth factor receptor (VEGFR) -targeting tyrosine kinase inhibitor or a mammalian target of rapamycin (mTOR) inhibitor.
  • Systemic chemotherapy and any liver-directed or other ablative therapy within 4 weeks before randomization.
  • Systemic radionuclide therapy within 6 weeks before randomization.
  • Radiation therapy for bone metastases within 2 weeks, any other radiation therapy, except as indicated above, within 4 weeks before randomization.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
440 participants (estimated)

Study arms

  • Active comparator
    Everolimus

    Participants will receive everolimus oral tablets once daily.

    Drug: Everolimus

  • Experimental
    Zanzalintinib

    Participants will receive zanzalintinib oral tablets once daily.

    Drug: Zanzalintinib

Interventions

  • Administered as specified in the treatment arm.

    Also known as: XL092

  • Administered as specified in the treatment arm.

    Also known as: Afinitor

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)

    Time frame: Up to 48 months

Secondary outcomes

  1. PFS Per RECIST 1.1 as Assessed by Investigator

    Time frame: Up to 48 months

  2. Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR and Investigator

    Time frame: Up to 48 months

  3. Overall Survival (OS)

    Time frame: Up to 60 months

  4. Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR and Investigator

    Time frame: Up to 48 months

  5. Disease Control Rate (DCR) Per RECIST 1.1 as Assessed by BICR and Investigator

    Time frame: Up to 48 months

  6. Change From Baseline in Participant-Reported Global Health Status (GHS) and Disease-Related Symptoms as Assessed by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) Score

    Time frame: Up to 48 months

  7. Change From Baseline in Participant-Reported GHS and Disease-Related Symptoms as Assessed by EORTC Gastrointestinal Neuroendocrine Tumor module (QLQ-GI.NET21) Score

    Time frame: Up to 48 months

  8. Number of Participants With Adverse Events

    Time frame: Up to 48 months

07

Study locations

134 of 135 sites recruiting

Showing the first 100 of 135 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Chan JA, Strosberg JR, Yoo C, Singh S, Huang H, Goel M, Scheffold C, Capdevila J. STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors. Future Oncol. 2026 Sep 28:1-8. doi: 10.1080/14796694.2026.2733790. Online ahead of print. PubMed 42803451 ↗

Individual participant data

Plan to share: No

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jun 2029, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2025
First posted
Apr 24, 2025
StartActual
Jul 21, 2025
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added — first site in Mexico
Show 9 added (2 Spain, 2 Taiwan, 1 Belgium, 1 Italy, 1 United States, 1 Brazil, 1 Mexico)
  • Universitair Ziekenhuis Antwerpen (UZA) · Edegem, Belgium
  • Centro Di Riferimento Oncologico (CRO) Di Aviano · Aviano, Italy
  • Institut Catalá d'Oncologia- ICO L'Hospitalet · Barcelona, Spain
  • MD Anderson Cancer Center · Madrid, Spain
  • Linkou Chang Gung Memorial Hospital · Taoyuan, Taiwan
  • National Institute of Health · Bethesda, United States
  • National Cheng Kung University Hospital · Tainan, Taiwan
  • A.C. Camargo Cancer Center · São Paulo, Brazil
  • Instituto Nacional de Cancerología · Mexico City, Mexico
across 3 updates, Sep 29, 2026 – Oct 30, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42803451 ↗
Sep 29, 2026
Show all 3 updates
  1. Oct 30, 2026
    2 sites added — first site in Mexico
    Show 2 added (1 Brazil, 1 Mexico)
    • A.C. Camargo Cancer Center · São Paulo, Brazil
    • Instituto Nacional de Cancerología · Mexico City, Mexico
  2. Oct 23, 2026
    2 sites added
    Show 2 added (1 United States, 1 Taiwan)
    • National Institute of Health · Bethesda, United States
    • National Cheng Kung University Hospital · Tainan, Taiwan
    + 1 other change: verification date
  3. Sep 29, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42803451 ↗
    5 sites added
    Show 5 added (2 Spain, 1 Belgium, 1 Italy, 1 Taiwan)
    • Universitair Ziekenhuis Antwerpen (UZA) · Edegem, Belgium
    • Centro Di Riferimento Oncologico (CRO) Di Aviano · Aviano, Italy
    • Institut Catalá d'Oncologia- ICO L'Hospitalet · Barcelona, Spain
    • MD Anderson Cancer Center · Madrid, Spain
    • Linkou Chang Gung Memorial Hospital · Taoyuan, Taiwan

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06943755
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Jul 21, 2025
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Exelixis Clinical Trials
Contact
druginfo@exelixis.com
1-888-EXELIXIS (888-393-5494)
Backup or International
Contact
650-837-7400
Medical Director
study director · Exelixis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanzalintinib

Start the discussion